R A Scolyer
Overview
Explore the profile of R A Scolyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan S, Guitera P, Ferguson P, El Sharouni M, Teh R, Scolyer R, et al.
J Eur Acad Dermatol Venereol
. 2024 Jun;
39(3):594-603.
PMID: 38925576
Background: Only a small per cent of new melanocytic lesions developing in adults are expected to represent melanomas. Total body photography (TBP) has been widely incorporated in clinical practice, especially...
2.
Pinkham M, Herschtal A, Hong A, Chua M, Scolyer R, Cumming S, et al.
Ann Surg Oncol
. 2024 Jun;
31(9):6118-6119.
PMID: 38914835
No abstract available.
3.
Pinkham M, Herschtal A, Hong A, Chua M, Scolyer R, Cumming S, et al.
Ann Surg Oncol
. 2024 Jun;
31(9):6088-6096.
PMID: 38851639
Background: Cutaneous neurotropic melanoma (NM) of the head and neck (H&N) is prone to local relapse, possibly due to difficulties widely excising the tumor. This trial assessed radiation therapy (RT)...
4.
Williams G, Quinn T, Lo S, Guitera P, Scolyer R, Thompson J, et al.
J Eur Acad Dermatol Venereol
. 2024 Jun;
39(2):416-425.
PMID: 38842170
Background: The use of Mohs micrographic surgery (MMS) in melanoma treatment has divided opinion and evidence-based guidelines are lacking. Objectives: This systematic review aimed to analyse clinical outcomes for patients...
5.
Menzies A, Lo S, Saw R, Gonzalez M, Chng S, Nieweg O, et al.
Ann Oncol
. 2024 May;
35(8):739-746.
PMID: 38754780
Background: Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report 5-year outcomes from the phase II...
6.
Schmitt C, Hoefsmit E, Fangmeier T, Kramer N, Kabakci C, Vera Gonzalez J, et al.
Cancer Immunol Immunother
. 2023 Aug;
72(11):3475-3489.
PMID: 37606856
Background: Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality...
7.
Versluis J, Menzies A, Sikorska K, Rozeman E, Saw R, van Houdt W, et al.
Ann Oncol
. 2023 Jan;
34(4):420-430.
PMID: 36681299
Background: Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in patients with macroscopic stage III melanoma. These response rates translated to high short-term survival rates. However, data on long-term...
8.
Rawson R, Vergara I, Stretch J, Saw R, Thompson J, Lo S, et al.
Pathology
. 2023 Jan;
55(2):214-222.
PMID: 36646575
Desmoplastic melanoma (DM) is an uncommon subtype of melanoma with distinct clinicopathological features. It is classified into pure desmoplastic melanoma (PDM) when the proportion of desmoplastic melanoma is ≥90% of...
9.
Ho G, Schwartz R, Regio Pereira A, Dimitrou F, Paver E, McKenzie C, et al.
J Eur Acad Dermatol Venereol
. 2022 Mar;
36(7):e583-e585.
PMID: 35285090
No abstract available.
10.
Schwartz R, Ho G, Smith A, Collgros H, Regio Pereira A, Gouveia B, et al.
J Eur Acad Dermatol Venereol
. 2022 Jan;
36(6):e445-e448.
PMID: 35043483
No abstract available.